Skip to main content
Toggle navigation
Login
Search
Home
Schedule at a Glance
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back
Favorite
Email
Tweet
Print
Rheanna Carter, MBA
Sr Manager, Business Development
BostonGene, Inc.
Poster(s):
(P 106) DELTAREX-G, A TUMOR TARGETED CCNG1 INHIBITOR, DEMONSTRATES CLINICAL BENEFIT IN ADVANCED CHEMORESISTANT SARCOMA FOLLOWING FDA CBER AUTHORIZATION FOR USE AS PLATFORM THERAPY WITH FDA APPROVED DRUGS
Email Rheanna
